<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150630</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000675485</org_study_id>
    <secondary_id>PACT-15</secondary_id>
    <secondary_id>2010-019942-23</secondary_id>
    <nct_id>NCT01150630</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer</brief_title>
  <acronym>PACT-15</acronym>
  <official_title>Randomized Phase II-III Trial of Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin,
      epirubicin hydrochloride, and capecitabine, work in different ways to stop the growth of
      tumor cells, either by killing the cells or by stopping them from dividing. Giving
      gemcitabine hydrochloride, with or without cisplatin, epirubicin hydrochloride, and
      capecitabine before surgery may make the tumor smaller and reduce the amount of normal tissue
      that needs to be removed. Giving these drugs after surgery may kill any tumor cells that
      remain after surgery.

      PURPOSE: This randomized phase II/III trial is studying how well gemcitabine hydrochloride,
      with or without cisplatin, epirubicin hydrochloride, and capecitabine, works when given
      before and/or after surgery in treating patients with stage I or stage II pancreatic cancer
      that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the proportion of patients who are event-free (defined as disease progression,
           local recurrence, distant metastasis, new tumor, or death) at 1 year after neoadjuvant
           therapy comprising gemcitabine hydrochloride with cisplatin, epirubicin hydrochloride,
           and capecitabine (PEXG), and adjuvant chemotherapy comprising gemcitabine hydrochloride
           or PEXG regimen in patients with resectable stage I or II adenocarcinoma of the
           pancreas. (phase II)

        -  To assess whether the best experimental regimen, which will be selected on the basis of
           the phase II part of the trial, is able to improve overall survival when compared to
           standard adjuvant gemcitabine in these patients. (phase III)

      Secondary

        -  To assess radiological, biochemical, and pathological response rate (neoadjuvant arm
           only) in these patients.

        -  To assess surgical resection rate, surgical mortality and morbidity, and proportion of
           patients with negative surgical margins.

        -  To assess lymph node status in these patients.

        -  To determine tolerability of these regimens in these patients.

      OUTLINE: This is a multicenter study. Patients are stratified according to center. Patients
      are randomized to 1 of 3 treatment arms.

        -  Arm I (adjuvant gemcitabine hydrochloride) : Patients receive gemcitabine hydrochloride
           IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days for 6 months in the
           absence of disease progression or unacceptable toxicity.

        -  Arm II (adjuvant cisplatin, epirubicin hydrochloride, gemcitabine hydrochloride, and
           capecitabine [PEXG regimen]): Patients receive cisplatin IV over 1 hour on days 1-5,
           epirubicin hydrochloride IV on days 1 and 8, gemcitabine hydrochloride IV over 1 hour on
           days 1 and 8, and oral capecitabine on days 1-14. Treatment repeats every 14 days for 6
           months in the absence of disease progression or unacceptable toxicity.

        -  Arm III (neoadjuvant and adjuvant PEXG regimen): Patients receive neoadjuvant cisplatin
           IV over 1 hour on days 1-5, epirubicin hydrochloride IV on days 1 and 8, gemcitabine
           hydrochloride IV over 1 hour on days 1 and 8, and oral capecitabine on days 1-14.
           Treatment repeats every 14 days for up to 3 months. Patients then undergo surgery for
           pancreatic cancer followed by adjuvant (within 2 months of surgery) PEXG given as in
           neoadjuvant therapy. Treatment with adjuvant PEXG repeats every 14 days for 3 months in
           the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year,
      every 4 months for 2 years, and then every 6 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival at 1 year (phase II)</measure>
    <time_frame>every 3 months</time_frame>
    <description>CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological, biochemical, and pathological response rate (neoadjuvant arm only)</measure>
    <time_frame>after 3 months of induction therapy</time_frame>
    <description>CT scan, CA19.9 serology; pathology report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical resection rate</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>surgeon report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical mortality and morbidity</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>surgeon report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>every 2 weeks during therapy</time_frame>
    <description>outpatient visit; laboratory report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with negative surgical margins</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>pathology report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node status</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>pathology report</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>adjuvant PEXG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>perioperative PEXG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1250 mg/mq/day per os for 14 days every 14 days for 6 months</description>
    <arm_group_label>adjuvant PEXG</arm_group_label>
    <arm_group_label>perioperative PEXG</arm_group_label>
    <other_name>XELODA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>30 mg/mq every 14 days for 6 months</description>
    <arm_group_label>adjuvant PEXG</arm_group_label>
    <arm_group_label>perioperative PEXG</arm_group_label>
    <other_name>cisplatino TEVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>30 mg/mq every 14 days for 6 months</description>
    <arm_group_label>adjuvant PEXG</arm_group_label>
    <arm_group_label>perioperative PEXG</arm_group_label>
    <other_name>farmorubicina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months</description>
    <arm_group_label>adjuvant PEXG</arm_group_label>
    <arm_group_label>perioperative PEXG</arm_group_label>
    <arm_group_label>Adjuvant Gemcitabine</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically* confirmed adenocarcinoma of pancreas

               -  Stage I-II disease

               -  Resectable disease

          -  No superior mesenteric vein or artery, portal vein, celiac trunk, or hepatic artery
             infiltration

          -  No symptomatic duodenal stenosis

          -  NOTE: Patients without histological or cytological results may be allowed provided ≥ 1
             attempt has been made by needle aspiration with negative imaging and clinical signs
             suggestive of adenocarcinoma.

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  WBC ≥ 3,500/mm³

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL

          -  Creatinine ≤ 1.5 mg/dL

          -  ALT and AST ≤ 3 times upper limit of normal

          -  Bilirubin ≤ 3 mg/dL

          -  No prior or concurrent malignancy within the past 5 years except for surgically cured
             carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin

          -  Not pregnant or nursing

          -  No psychological, familial, sociological, or geographical condition that would
             potentially hinder study compliance or follow-up schedule

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy for pancreatic adenocarcinoma

          -  No other concurrent experimental drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Reni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico H. San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Scientifico H. San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Michele Reni</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

